These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24434633)

  • 1. Laboratory investigation of platelet function in patients with thalassaemia.
    Theodoridou S; Economou M; Vyzantiadis TA; Teli A; Vlachaki E; Neokleous N; Kargioti A; Vakalopoulou S; Garypidou V; Gombakis N; Papachristou F
    Acta Haematol; 2014; 132(1):45-8. PubMed ID: 24434633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
    Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E; Christoulas D; Terpos E
    Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
    Genc GE; Ozturk Z; Gumuslu S; Kupesiz A
    Biol Trace Elem Res; 2016 Mar; 170(1):9-16. PubMed ID: 26179086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating platelet function disorders in children with bleeding tendency - A single center study.
    Tanous O; Steinberg Shemer O; Yacobovich J; Zoldan M; Horovitz Y; Yaniv I; Rabizadeh E; Tamary H; Nakav S; Lahav J
    Platelets; 2017 Nov; 28(7):676-681. PubMed ID: 28060550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
    Christoforidis A; Perifanis V; Tsatra I; Vlachaki E; Athanassiou-Metaxa M
    Diabetes Res Clin Pract; 2007 Apr; 76(1):6-11. PubMed ID: 16930760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco].
    Agouzal M; Quyou A; Benchekroune K; Khattab M
    Rev Med Brux; 2010; 31(2):79-87. PubMed ID: 20677662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
    Dyszkiewicz-Korpanty A; Olteanu H; Frenkel EP; Sarode R
    Platelets; 2007 Nov; 18(7):491-6. PubMed ID: 17852774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G; Lindeman R
    Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
    Origa R; Danjou F; Cossa S; Matta G; Bina P; Dessì C; Defraia E; Foschini ML; Leoni G; Morittu M; Galanello R
    Br J Haematol; 2013 Nov; 163(3):400-3. PubMed ID: 24033185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.
    Velik-Salchner C; Maier S; Innerhofer P; Kolbitsch C; Streif W; Mittermayr M; Praxmarer M; Fries D
    Anesth Analg; 2009 Jun; 108(6):1747-54. PubMed ID: 19448196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation.
    Escolar G; Cases A; Viñas M; Pino M; Calls J; Cirera I; Ordinas A
    Haematologica; 1999 Jul; 84(7):614-9. PubMed ID: 10406903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of light transmission aggregometry and multiple electrode aggregometry for the evaluation of patients with mucocutaneous bleeding.
    Sun P; McMillan-Ward E; Mian R; Israels SJ
    Int J Lab Hematol; 2019 Feb; 41(1):133-140. PubMed ID: 30358923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.
    Zanninelli G; Breuer W; Cabantchik ZI
    Br J Haematol; 2009 Dec; 147(5):744-51. PubMed ID: 19764989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.